How does the choice between culture and toxin-based testing influence diagnostic strategies for suspected C. difficile infection?

• A. NAAT (PCR) for toxin genes is often used; toxin assays detect active toxin-mediated disease; culture can detect toxin producers but is slower.
• B. Culture alone is sufficient.
• C. Serology is the primary test.
• D. Imaging is diagnostic.

Answer: (A)

Diagnosing suspected C. difficile infection hinges on matching the test to what’s causing disease in the gut: active toxin production versus just the presence of the organism. NAATs that detect toxin genes are fast and sensitive and are commonly used as an initial screen because they quickly tell you if a toxigenic C. difficile strain is present. But finding the gene doesn’t prove that toxin is currently being made or that there is toxin in the stool at illness onset, so you still need a test that confirms active toxin.

Toxin assays, which detect the actual toxins A or B in stool, are important because they link testing to the patient’s current symptoms and confirm toxin-mediated disease. Culture can identify C. difficile and determine whether the strain is toxigenic, but it’s slow and, on its own, doesn’t prove active toxin production in the patient at that moment, so it isn’t ideal for immediate diagnosis or management.

Because each method has limitations, diagnostic strategies often use a combination or sequential approach: a sensitive screening test to detect potential toxigenic presence, followed by a toxin assay to confirm active disease and differentiate infection from colonization. Imaging and serology are not used as primary diagnostic tools for acute CDI; imaging shows complications but doesn’t diagnose infection, and serology does not reliably reflect current toxin production or disease activity.